Results 71 to 80 of about 985,459 (298)

Abatacept for Prophylaxis of Acute and Chronic Graft‐Versus‐Host‐Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta‐Analysis of Cohort Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Graft‐versus‐host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T‐cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
Matthijs D. Kruizinga, Anne B. Verbeek, Caroline A. Lindemans, Emilie P. Buddingh   +3 more
wiley   +1 more source

Selective JAK inhibitor: Abrocitinib (JAK1-Selective)

Değer Dil Düzenle The JAK signaling pathway has a critical role in the pathogenesis of various chronic inflammatory diseases, such as atopic dermatitis.
Şeker, Ümmühan, Aydoğan, Kenan
core   +1 more source

Recalcitrant Eyelid Lupus Treated With Topical Ruxolitinib

JEADV Clinical Practice
Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events.
Clémence Bertold, Feriel Boukari, Valérie Elmaleh, Julia Bonnelye, Ulysse Jacquier, Nathalie Cardot‐Leccia, Thierry Passeron   +6 more
doaj   +1 more source

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Rebecca J. Deyell, Lesleigh Abbott, Tony H. Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +21 more
wiley   +1 more source

Upadacitinib in nail psoriasis: a case report

Journal of Dermatological Treatment, 2023
The purpose of the article Nail psoriasis is a refractory disease that affects 50–79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA).
Na Wang, Qing Yang, Yongxia Liu, Hong Liu   +3 more
doaj   +1 more source

Experience With Performing Rheocarna Therapy via the Single‐Needle Method for Treatment of Chronic Limb‐Threatening Ischemia

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds. Methods Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment.
Yasutaka Yamauchi, Rie Tanaka, Reona Kawahira, Shingo Nabeta, Kouhei Naoi, Kazuhito Kitajima, Akira Wada, Tomonari Takagi, Norihiko Ohura, Akira Miyamoto   +9 more
wiley   +1 more source

Selective JAK Inhibitor: Ritlecitinib

Ritlecitinib, a selective Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family inhibitor, exhibits promising potential as an effective therapeutic modality for addressing alopecia areata and vitiligo.

core   +1 more source

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis [PDF]

, 2018
Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activation loop phosphorylation and is associated with a life-threatening cytokine-rebound syndrome if rapidly withdrawn.
David M. Ross, Angel F. Lopez, Denis Tvorogov, Parker, MW, Kan, W.L., Dottore, M, Liau, N.P.D., Tvorogov, D, Barry, EF, Barry, E.F., Stomski, F, Majeti, R., Majeti, R, Babon, JJ, Mara Dottore, Jeffrey J. Babon, Nicholas P. D. Liau, Liau, NPD, Emma F. Barry, Hercus, TR, Tergaonkar, V, Timothy P. Hughes, Tergaonkar, V., Kan, WL, Ross, DM, Ross, D.M., Thomas, D, Winnie L. Kan, Tvorogov, D., Hercus, T.R., Lathi, M, Frank Stomski, Lopez, AF, Daniel Thomas, Dottore, M., Hughes, T.P., Parker, M.W., Michael W. Parker, Ravindra Majeti, Stomski, F., Babon, J.J., Lopez, A.F., Vinay Tergaonkar, Maya Lathi, Timothy R. Hercus, Lathi, M., Thomas, D., Hughes, TP   +47 more
core   +1 more source

Forecasting the Dialysis Burden in Japan: Validation‐Based Projections of Prevalence and Incidence Through 2050

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Japan has one of the highest dialysis prevalence rates worldwide and a shrinking, aging population. Whether dialysis burden has entered a sustained post‐peak phase or whether recent declines partly reflect pandemic‐related disruptions remains uncertain.
Hatice Şahin, Berrak Itır Aylı, Nüket Paksoy   +2 more
wiley   +1 more source